Stocks · News reference

Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

Jun 18, 2026, 5:42 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 11:18 AMBenzinga Newsdesk
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share
NMRA
SEC EDGARAug 14, 2026, 11:13 AMSEC EDGAR
8-K filing — Neumora Therapeutics, Inc. (NMRA)
Filed: 2026-08-14 AccNo: 0001193125-26-350349 Size: 345 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
NMRA
BenzingaJul 31, 2026, 5:24 PMVandana Singh
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
BIOA NMRA NVO
BenzingaJul 31, 2026, 4:16 PMBenzinga Newsdesk
Neumora Therapeutics shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.
NMRA